No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Ixico announced further validation of its AI-driven imaging platform IXIQ.Ai in Huntington's disease (HD) research on Wednesday, through its collaboration with the Huntington's Disease Imaging Harmonisation (HD-IH) consortium.
The AIM-traded company said the breakthrough strengthened its position in neurological disease analysis, and would open additional revenue opportunities.
It said HD-IH had completed the analysis of over 6,000 MRI datasets, the largest imaging dataset for Huntington's disease to date.
Using that data, Ixico said it had updated the HD-Integrated Staging System (HD-ISS) cut-off values, which guide disease diagnosis, severity assessment, and treatment decisions.
Ixico said its proprietary deep learning algorithm had demonstrated the ability to accurately measure volumetric changes in key brain regions affected by Huntington's disease, providing deeper insights into disease progression.
The firm said it was also working with key opinion leaders to explore the use of brain volume measurements as a surrogate endpoint in clinical trials, potentially offering an alternative to traditional clinical outcomes.
"HD-ISS provides an evidence- based biomarker-based framework for the biological definition of HD," said Ixico's chief scientific officer Robin Wolz.
"The completion of HD-ISS staging cut-off points is an important achievement in the HD-IH consortium."
Wolz said the relevant brain volume measures in a highly accurate and automated tool like IXIQ.Ai allowed "reliable and robust" implementation of the staging system in HD clinical trials.
"With this major milestone, we will focus with our partners to put those measures into clinical trial use and build further evidence towards the use of brain volumetric measures as surrogate endpoints."
At 1356 GMT, shares in Ixico were up 3.83% at 12.2p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
